作者: Michael Pezold , Geoffrey K. Ku , Larissa K. Temple
DOI: 10.1007/978-3-319-40223-9_14
关键词:
摘要: One in five patients diagnosed with colorectal cancer (CRC) present synchronous metastatic disease, and of these, only 13 % survive to 5 years [1]. Curative resection the primary tumor metastases can improve 5-year overall survival (OS) 30–50 [2]. Unfortunately, about three-quarters CRC unresectable disease liver [3]. In this setting, principal treatment is chemotherapy, an median randomized-controlled trials >20 months [4, 5]; fact, a recent phase III study suggested that who were able receive all currently available systemic options had OS nearly 30 [6].